javitt: we have two programs underway.tment that is under review by fda for emergency use. that is a treatment that will hopefully help people who are already in the icu, who have already developed covid, and who are struggling to survive. no question, no matter how good the vaccines get, the virus will always try to stay ahead of us, and we need something for people who suffer from breakthrough infections. at the same time, we are working on a vaccine in partnership with the government of israel, israel institute of biological research, targeting these covid variants that are bypassing the first generation vaccines. the virus is mutating every day. with each mutation, the vaccines that we all lined up for last year are less and less able to keep up. matt: really appreciate your time. sorry we got cut a little short as president biden came on to talk about the response to ida. we hope that we can get you back on. dr. jonathan javitt, the ceo of nrx pharmaceuticals talking about the vaccination and treatment for covid-19. f